Updated hourlyHourly refreshWed, Jul 22, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare
(PR-inside.com) TORONTO, ON / ACCESS Newswire / July 21, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the appointment of Steven Price as co-leader of its Life Sciences & Healthcare Practice. Price will join John Blank in leading the practice as Caldwell continues to expand its capabilities across the life sciences and healthcare sectors. Steven Price has been appointed co-leader of Caldwell's Life Sciences & Healthcare Practice Caldwell's Life Sciences & Healthcare Practice advises pharmaceutical, biotechnology, medical device, diagnostics, healthcare services, academic medicine and healthcare technology organizations on board, CEO and senior executive appointments. The practice helps clients recruit leaders ..
Jul 21 · 15:05·PR-Inside
AI
Transparency Coalition mid-year report finds 27 states actively advancing artificial intelligence protections for citizens SEATTLE, July 21, 2026 /PRNewswire-PRWeb/ -- State lawmakers passed or enacted 84 new AI-related laws across 27 states during the first half of 2026, according to a...
Jul 21 · 15:05·PRWeb
Automotive
(PR-inside.com) The award recognizes influential voices in Fort Lauderdale's many industries. FORT LAUDERDALE, FL / ACCESS Newswire / July 21, 2026 / Every year,Fort Lauderdale Magazinereleases a list of some of the most influential professionals in the area. This list reflects the efforts of local professionals who've positively impacted the lives of locals and who continue to dedicate themselves to the betterment of the community. This award specifically recognizesJarrett Blakeley 's unending fight for clients' financial justice. Since opening Blakeley Car Accident & Personal Injury Lawyers in 2006, Mr. Blakeley and his Fort Lauderdale personal injury lawyers have put over $250 million back ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Celcuity Inc. ("Celcuity" or "the Company") (NASDAQ:CELC). Investors who purchased Celcuity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/CELC. Celcuity Investigation Details On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and "anticipates commercial launch in late Q3 2026", representing a delayed launch timeline relative to analyst expectations. Commenting on ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pentair plc ("Pentair" or "the Company") (NYSE:PNR). Investors who purchased Pentair securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/PNR. Pentair Investigation Details On July 14, 2026, Pentair issued a press release announcing its preliminary second quarter 2026 financial results and revising its full year 2026 guidance. For the second quarter, Pentair reported that "[s]ales are expected to be approximately $930 million, down 17 percent versus previous guide of ..
Jul 21 · 15:04·PR-Inside
Finance · AI
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AppLovin Corporation ("AppLovin" or "the Company") (NASDAQ:APP). Investors who purchased AppLovin securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/APP. AppLovin Investigation Details On July 13, 2026, a Bank of America Securities analyst published a note reporting softer-than-expected e-commerce ad growth for the month of June, raising concerns over the rollout of AppLovin's new AI-driven merchant platform. Following publication of the note, AppLovin's stock price fell $64.13 per share, ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of International Business Machines Corporation ("IBM" or "the Company") (NYSE:IBM). Investors who purchased IBM securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/IBM. IBM Investigation Details On July 14, 2026, IBM reported its preliminary Q2 2026 financial results. The Company fell short of analyst expectations, with CEO Arvind Krishna blaming the shortfall on weakness in the software and infrastructure business, with customers shifting budgets to hardware like memory chips. Following ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AstraZeneca PLC ("AstraZeneca" or "the Company") (NYSE:AZN). Investors who purchased AstraZeneca securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/AZN. AstraZeneca Investigation Details On July 9, 2026, AstraZeneca disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with Ionis Pharmaceuticals, did not meet its primary endpoint. Following this news, AstraZeneca's American Depositary Share ("ADS") price fell $10.79 per ADS, or 5.7%, to ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. ("Ionis" or "the Company") (NASDAQ:IONS). Investors who purchased Ionis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/IONS. Ionis Investigation Details On July 9, 2026, Ionis disclosed that the late-stage Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with AstraZeneca, did not meet its primary endpoint. Following this news, Ionis's stock price fell $20.19 per share, or 23.9%, to close at $64.27 ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Snowflake Inc. ("Snowflake Inc." or "the Company") (NYSE:SNOW). Investors who purchased Snowflake Inc. securities prior to June 27, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/SNOW. Snowflake Inc. Investigation Details The investigation concerns whether Snowflake Inc. and certain of its officers and/or directors have engaged in corporate wrongdoing. What's Next for Snowflake Inc. Investors? If you are aware of any facts relating to ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Franklin Covey Co. ("Franklin Covey" or "the Company") (NYSE:FC). Investors who purchased Franklin Covey securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/FC. Franklin Covey Investigation Details On July 1, 2026, Franklin Covey issued a press release reporting its financial results for the third quarter of its 2026 fiscal year. Among other items, Franklin Covey reported revenue of only $67.81 million, missing the consensus estimate of $68.33 million, and ..
Jul 21 · 15:04·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / July 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solstice Advanced Materials, Inc. ("Solstice" or "the Company") (NASDAQ:SOLS). Investors who purchased Solstice securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:bgandg.com/SOLS. Solstice Investigation Details On July 6, 2026, Solstice issued a press release announcing an agreement to acquire Element Solutions ("Element") "in a cash-and-stock transaction valued at approximately $14.5 billion, including the assumption of net debt." Although Solstice's Chief Executive Officer described the "combined company [as] very well-positioned ..
Jul 21 · 15:03·PR-Inside